Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Total Current Liabilities: 2022-2024

Historic Total Current Liabilities for Taysha Gene Therapies (TSHA) over the last 3 years, with Dec 2024 value amounting to $26.2 million.

  • Taysha Gene Therapies' Total Current Liabilities fell 2.40% to $28.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year decrease of 2.40%. This contributed to the annual value of $26.2 million for FY2024, which is 28.65% down from last year.
  • According to the latest figures from FY2024, Taysha Gene Therapies' Total Current Liabilities is $26.2 million, which was down 28.65% from $36.8 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Total Current Liabilities registered a high of $62.8 million during FY2022, and its lowest value of $26.2 million during FY2024.
  • Over the past 3 years, Taysha Gene Therapies' median Total Current Liabilities value was $36.8 million (recorded in 2023), while the average stood at $41.9 million.
  • Data for Taysha Gene Therapies' Total Current Liabilities shows a maximum YoY crashed of 41.46% (in 2023) over the last 5 years.
  • Taysha Gene Therapies' Total Current Liabilities (Yearly) stood at $62.8 million in 2022, then slumped by 41.46% to $36.8 million in 2023, then fell by 28.65% to $26.2 million in 2024.